| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third quarter revenue grew 14% year-over-year to $50.2 million |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Second quarter revenue grew 8% year-over-year to $49.0 million |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
(as amended by the First Amendment (effective February 25, 2021), the Second Amendment (effective April 30, 2021), the Third Amendment (effective May 17, 2024), and the Fourth Amendment (effective June 5, 2026)) |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
First quarter revenue grew 16% year-over-year to $47.8 million |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Third quarter revenue increased 15% year-over-year to $44.2 million |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Second quarter revenue increased 14% year-over-year to $45.5 million |
| 13 Jun 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
On June 11, 2025, the Company completed the previously disclosed divestiture of its CRYOPDP Business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million. Pursuant to the terms of the Agreeme... |
| 10 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2025, Cryoport, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of stockholders at the Annual Meeting, each of which is d... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year |
| 31 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Cryoport Inc, a corporation incorporated under the laws of the State of Nevada (United States of America) having its registered office at 112 Westwood Place – Suite 350, Brentwood Tennessee 37027, |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition
FY 2024 revenue of $228.4 million, in-line with company guidance |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition
Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially |
| 06 Aug 2024 |
8-K: Other Events
$200 million repurchase program authorized to repurchase common stock and/or convertible notes |
| 22 May 2024 |
8-K: Submission of Matters to a Vote of Security Holders
1.1 Establishment; Impact on Prior Plans. Cryoport, Inc. (the “Company”) hereby establishes the “Cryoport, Inc. 2018 Omnibus Equity Incentive Plan” (the “Plan”). The Plan will supersede and replace the Cryoport, Inc. 2015 Omnibus Equity ... |
| 07 May 2024 |
8-K: Results of Operations and Financial Condition
9% year-over-year increase in Commercial Cell & Gene Therapy revenue |
| 12 Mar 2024 |
8-K: Results of Operations and Financial Condition
Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% |
| 15 Feb 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 15, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Mark Sawicki (“Ex... |
| 15 Nov 2023 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
(a) An annual meeting of the stockholders, for the purpose of the election of directors to succeed those whose terms may expire in such year and for the transaction of such other business as may properly come before the meeting, shall be... |
Loading...